Search

Search Constraints

You searched for: Author/Creator Johanson, Per

Search Results

2. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial. Issue 10 (18th May 2020)

3. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Issue 8 (25th August 2020)

4. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Issue 22 (28th May 2019)

5. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Issue 17 (27th October 2020)

6. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Issue 4 (20th June 2019)

7. Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial. Issue 10 (18th May 2020)

8. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. (7th December 2019)

9. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. (11th November 2022)

10. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54. Issue 22 (20th November 2018)